HALB News and Press, Tykhe Corp From 11/14/22

* Accelerated Sales of HALB's Patented Products through newly formed "The Hamden Group" . JACKSON CENTER, PA / ACCESSWIRE / November 14, 2022 / Halberd Corporation (OTC-PINK:HALB) has signed a contract with the Hamden Group. The Hamden Group is a newly formed corporation which consists...

JACKSON CENTER, PA / ACCESSWIRE / October 27, 2022 / Halberd Corporation (OTC PINK:HALB) Chairman, President and CEO William A. Hartman and Chief Technology Officer, Dr. Mitchell S. Felder, interviewed on "The Street Reports," speaking about significant milestones which their research demo...

Could be Instrumental in Curing Sepsis, Meningitis Among Other Life-Threatening Diseases Jackson Center, Pennsylvania--(Newsfile Corp. - October 18, 2022) - Halberd Corporation (OTC Pink: HALB) has successfully eliminated various antibiotic resistant bacteria from buffer solution in-vitro thr...

Could be Instrumental in Curing Sepsis, Meningitis Among Other Life-Threatening Diseases JACKSON CENTER, PA / ACCESSWIRE / October 18, 2022 / Halberd Corporation (OTC PINK:HALB) has successfully eliminated various antibiotic resistant bacteria from buffer solution in-vitro through the...

Excess IL-6 is associated with inflammation in rheumatoid arthritis, MS, some cancers and neurodegenerative diseases. Jackson Center, Pennsylvania--(Newsfile Corp. - October 12, 2022) - Halberd Corporation (OTC Pink: HALB) demonstrated the removal of Interleukin-6 (IL-6) from human blood seru...

Jackson Center, Pennsylvania--(Newsfile Corp. - September 27, 2022) - Halberd Corporation (OTC Pink: HALB )  entered into a strategic alliance with AI Longevity, Inc. and Stem of Hope to form a strategic alliance as a wholly owned subsidiary of Halberd Corporation named "Extendalife TM "....

Jackson Center, Pennsylvania--(Newsfile Corp. - August 23, 2022) - Halberd Corporation (OTC Pink: HALB) researchers have demonstrated the ability to precisely control the level of PD-1 in human blood serum in laboratory in-vitro testing. PD-1 (programmed cell death-1) is a T-Cell protein which...

Jackson Center, Pennsylvania--(Newsfile Corp. - August 4, 2022) - Halberd Corporation (OTC Pink: HALB) has received a letter of endorsement from Carl Eller, President of the NFL Retired Players Association (NFL RPA), for Halberd's research work in the development of treatments for Traumatic Br...

Phoenix, Arizona--(Newsfile Corp. - July 28, 2022) - The Stock Day Podcast welcomed Halberd Corporation (OTC Pink: HALB), a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Chairman, CEO and President of the Company, William Hartman, ...

Halberd ( OTCPK:HALB ) has announced the formation of Halberd Cancer Therapeutics, as a wholly owned subsidiary. Halberd's patented extracorporeal technology has demonstrated the capacity for successful application to a wide variety of diseases and health-related illnesses. ...